Aptus Capital Advisors LLC Has $12.53 Million Stock Holdings in Amgen Inc. $AMGN

Aptus Capital Advisors LLC trimmed its position in Amgen Inc. (NASDAQ:AMGN) by 3.4% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 44,387 shares of the medical research company’s stock after selling 1,546 shares during the period. Aptus Capital Advisors LLC’s holdings in Amgen were worth $12,526,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Sequoia Financial Advisors LLC lifted its position in Amgen by 2.3% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 160,646 shares of the medical research company’s stock valued at $45,334,000 after purchasing an additional 3,619 shares during the period. Atlantic Union Bankshares Corp grew its position in shares of Amgen by 165.0% during the 2nd quarter. Atlantic Union Bankshares Corp now owns 10,643 shares of the medical research company’s stock worth $2,972,000 after buying an additional 6,627 shares during the period. Davis Capital Management bought a new stake in shares of Amgen during the third quarter worth approximately $1,841,000. D.A. Davidson & CO. raised its stake in shares of Amgen by 2.6% during the third quarter. D.A. Davidson & CO. now owns 243,054 shares of the medical research company’s stock worth $68,590,000 after buying an additional 6,222 shares during the last quarter. Finally, Global Wealth Management Investment Advisory Inc. lifted its holdings in Amgen by 56.2% in the third quarter. Global Wealth Management Investment Advisory Inc. now owns 13,056 shares of the medical research company’s stock valued at $3,684,000 after buying an additional 4,699 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Royal Bank Of Canada lifted their target price on shares of Amgen from $335.00 to $360.00 and gave the stock an “outperform” rating in a report on Wednesday, February 4th. Deutsche Bank Aktiengesellschaft increased their price target on Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a research note on Thursday, February 5th. DZ Bank lifted their price objective on Amgen from $335.00 to $364.00 in a research note on Monday, November 10th. Cantor Fitzgerald upped their price objective on Amgen from $315.00 to $350.00 and gave the company a “neutral” rating in a report on Wednesday, February 4th. Finally, Morgan Stanley increased their target price on Amgen from $304.00 to $309.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 4th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, twelve have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $354.17.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen’s recent quarter beat revenue and EPS estimates and management issued FY‑2026 EPS guidance, which supports the buy thesis and helped lift sentiment. Why Is Amgen (AMGN) Up 3.6% Since Last Earnings Report?
• Positive Sentiment: The board declared a $2.52 quarterly dividend (ex‑dividend May 15), reinforcing shareholder returns and supporting income‑oriented demand for the stock. AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND
• Neutral Sentiment: Amgen will present at the Leerink Partners 2026 Global Healthcare Conference (Mar 11). The fireside chat with the CFO and rare‑disease head could provide more detail on pipeline priorities and capital allocation — a potential catalyst depending on the tone. AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE
• Neutral Sentiment: Short‑interest data reported for early March appears to show no meaningful short position (entries list zeros/NaN), which suggests short sellers are not a large immediate pressure point — note the data may reflect reporting quirks.
• Negative Sentiment: Amgen and partner Kyowa Kirin halted all rocatinlimab trials after safety signals linking OX40 pathway modulation to malignancies. Losing a late‑stage immunology asset is a clear pipeline setback and could reduce upside from future launches. Amgen Faces Rocatinlimab Halt And Rethinks Pipeline And Capital Priorities
• Negative Sentiment: Senate Democrats are pressing pharma companies over pricing deals tied to the prior administration, raising the risk of increased political and regulatory scrutiny that could pressure margins or pricing for large biopharma firms including Amgen. Pharma giants pressed by Senate Democrats over Trump pricing deals
• Negative Sentiment: At least one analyst piece has downgraded the stock to a “hold” / advised waiting for a better entry point, signaling some caution on valuation after the recent run. Amgen: Wait For A Better Entry Point (Rating Downgrade)

Amgen Stock Up 0.5%

Amgen stock opened at $369.53 on Friday. Amgen Inc. has a twelve month low of $261.43 and a twelve month high of $391.29. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The company has a 50 day moving average of $353.26 and a 200-day moving average of $322.43. The stock has a market capitalization of $199.20 billion, a PE ratio of 25.97, a price-to-earnings-growth ratio of 3.65 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating the consensus estimate of $4.76 by $0.53. The business had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm’s revenue was up 8.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be given a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio is currently 70.84%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.